Why Aptinyx Stock Soared on Friday
Shares of Aptinyx (NASDAQ: APTX), a clinical-stage biotech focused on the brain and nervous system, rose about 27% on Friday.
The double-digit jump appears to be linked to the filing of an SEC document that shows that Adams Street Partners -- an investment management company with $40 billion in assets -- has acquired more than 5 million shares of Aptinyx's stock. That position represents more than 11% of shares outstanding.
Image source: Getty Images.
Source Fool.com